What cardiovascular benefits have been associated with the use of retatrutide in clinical studies?

Retatrutide has demonstrated associations with several cardiovascular benefits, primarily by significantly improving key risk factors such as body weight, lipid profiles, blood pressure, and glycemic control in clinical studies. However, definitive evidence proving a reduction in major adverse cardiovascular events (MACE) is not yet available, as dedicated outcome trials are still ongoing.

What the AI assistants say

AI assistants largely agree that retatrutide, an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, shows significant promise for cardiovascular benefits primarily through its impact on metabolic risk factors. They consistently highlight its profound effects on weight loss, improved lipid profiles, reductions in blood pressure, and enhanced glycemic control.

Collectively, the AI assistants report the following findings from clinical studies:

• Significant Weight Loss

  This is considered a primary indirect cardiovascular benefit. Studies (Phase 2 and 3) showed mean body weight loss ranging from -24.2% (up to -26.2 kg) over 48 weeks with 12 mg in obesity, to -28.3% (TRIUMPH-1, Phase 3, 80 weeks, 12 mg, obesity) and -28.7% (TRIUMPH-4, Phase 3).

• Improved Lipid Profiles

  Retatrutide produced dose-dependent reductions in key lipid markers:

  • Non-HDL cholesterol: −22.2% (24 weeks) to −26.9% (48 weeks) with 12 mg.
  • Apolipoprotein B (apoB): −19.6% to −24.2% with 12 mg.
  • Triglycerides: −40.6% (24-48 weeks) to −41.0% (TRIUMPH-1) with 12 mg.
  • ApoC-III: −38.0% with 12 mg.
  • Small LDL particles: Reduced across all doses.
  • NMR-derived lipoprotein insulin resistance score: Decreased by 27.4% to 32.5% at 48 weeks.

• Blood Pressure Reduction

  Consistent lowering of blood pressure was observed:

  • Systolic BP: Reduced by −7.64 mmHg (Phase 2 pooled) to −12.3 mmHg (TRIUMPH-1, Phase 3).
  • Diastolic BP: Reduced by −2.33 mmHg (Phase 2 pooled) to −3.88 mmHg (meta-analysis).

• Improved Glycemic Control and Metabolic Markers

  • HOMA-IR (insulin resistance): Significantly improved at 24 and 48 weeks.
  • Fasting glucose: Reduced (meta-analysis MD: −23.51 mg/dL).
  • HbA1c (in T2D): Reduced up to −2.16% (12 mg, 36 weeks).
  • Branched-chain amino acids (BCAAs): Decreased −21% to −32% at 24 weeks with 12 mg.
  • 2-aminoadipic acid (2-AAA): Decreased −41.4% with 12 mg at 24 weeks.
  • Uric acid: Decreased −22.1% with 12 mg at 24 weeks.

• Inflammation Modulation

  Improvements in markers like hsCRP were reported.

• Underlying Mechanisms

  The triple agonism leads to:

  • GLP-1R: Increases insulin secretion, satiety, reduces gastric emptying and inflammation, and has direct vascular effects.
  • GIPR: Improves adipose tissue health, peripheral insulin sensitivity, and lipid metabolism.
  • GCGR (glucagon): Increases energy expenditure, lipolysis, reduces lipogenesis, and enhances hepatic fatty acid oxidation, contributing significantly to weight loss and reduced triglycerides.

  Metabolomic analysis also showed activation of fatty acid oxidation (FAO), indicated by increased 3-hydroxybutyrate (+198%) and C2/C0 carnitine ratio (+95.3%).

A key point of agreement across all AI assistants is that while these improvements in cardiovascular *risk factors* are significant, there is **no trial data yet proving a reduction in major adverse cardiovascular events (MACE)**. Dedicated cardiovascular outcome trials (e.g., TRIUMPH-CVOT, ~10,000 participants) are ongoing, with results expected in 2028–2029. Some AI assistants also note that retatrutide can increase heart rate, especially during titration, and discuss other potential indirect benefits like improved sleep apnea.

What the research actually shows

Retatrutide, also known as teriparatide, is a recombinant human parathyroid hormone (PTH) analog that has been primarily used for the treatment of osteoporosis. However, its potential cardiovascular benefits have been a subject of interest and investigation in various clinical studies. According to the provided sources, the cardiovascular benefits associated with retatrutide can be summarized as follows:

1. Vascular Function Improvement: In a study by Forst et al. (2012) [10], it was observed that the addition of liraglutide, a GLP-1 analog, in patients with type 2 diabetes well controlled on metformin monotherapy improved several markers of vascular function. Although this study specifically mentions liraglutide, it suggests that incretin-based therapies, which retatrutide is not a part of, may have positive effects on vascular function.
2. Inflammation Modulation: Hogan et al. (2014) [10] reported that glucagon-like peptide 1 (GLP-1) analog therapy, similar to retatrutide in its peptide hormone nature, directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. This suggests that peptide hormones like retatrutide could potentially have anti-inflammatory effects, which is beneficial for cardiovascular health.
3. Plasminogen Activator Inhibitor Type-1 Attenuation: Liu et al. (2009) [10] found that a long-acting GLP-1 analog attenuated the induction of plasminogen activator inhibitor type-1 (PAI-1) and vascular adhesion molecules. PAI-1 is a key factor in thrombosis and atherosclerosis, so reducing its levels could have positive cardiovascular implications, although this study does not directly involve retatrutide.
4. Barrier Protective Expression: Bang-Berthelsen et al. (2016) [10] showed that GLP-1 induces barrier protective expression in Brunner’s glands and regulates colonic inflammation. While this study is more focused on gastrointestinal health, the anti-inflammatory effects and barrier protection could potentially have indirect benefits on cardiovascular health by reducing systemic inflammation.
5. Gene Association with Atherosclerotic Phenotype: G. Pasterkamp et al. (2016) [10] validated genes associated with a murine atherosclerotic phenotype. This study provides insights into the genetic factors contributing to atherosclerosis, which could be relevant to the understanding of retatrutide’s potential effects on cardiovascular health, although it does not directly involve retatrutide.

It is important to note that while these studies provide insights into the potential cardiovascular benefits of peptide hormones, they do not directly involve retatrutide. The actual cardiovascular benefits of retatrutide would need to be determined through specific clinical trials designed to evaluate its effects on cardiovascular health. The studies mentioned here provide a broader context of how peptide hormones, similar in nature to retatrutide, may impact cardiovascular health, but they should not be taken as direct evidence of retatrutide’s effects.

Where the AI Consensus and Research Diverge

There is a significant divergence between the AI assistants’ consensus and the provided research corpus regarding the fundamental identity and reported benefits of retatrutide. The AI assistants consistently describe retatrutide as a novel GLP-1, GIP, and glucagon triple agonist (referring to the investigational drug LY3437943), detailing its impact on metabolic risk factors based on multiple specific clinical trials (Phase 2 and Phase 3). In stark contrast, the provided research corpus misidentifies “retatrutide” as teriparatide, a parathyroid hormone analog primarily used for osteoporosis, and subsequently discusses potential cardiovascular benefits extrapolated from studies involving *other* peptide hormones like liraglutide or GLP-1 analogs. The research corpus explicitly states that these studies “do not directly involve retatrutide” and “should not be taken as direct evidence of retatrutide’s effects.” Therefore, the specific, quantitative cardiovascular risk factor improvements reported by the AI assistants pertain to the triple agonist known as retatrutide (LY3437943), while the research corpus provides no direct evidence for this particular drug, instead referring to a different compound and other classes of peptide hormones.

Bottom line: While AI assistants identify substantial improvements in cardiovascular risk factors from retatrutide’s triple-agonist action, direct evidence for hard cardiovascular outcomes is still pending, and the provided research corpus discusses a different compound and other peptide hormones, rather than providing direct evidence for the specific drug known as retatrutide (LY3437943).

References

1. Biologic Therapy in Dermatology
2. Doping in Sports_ Biochemical Principles, Effects and Analysis
3. Endocrinology_ Adult and Pediatric
4. Essential Atlas of Heart Diseases
5. Estrogens and Progestogens in Clinical Practice.partial
6. GHRH, GH, and IGF-1_ Basic and Clinical Advances
7. GLP-1 Receptor Agonists in Type 2 Diabetes
8. GLP-1 and the kidney_ from physiology to pharmacology and outcomes in diabetes
9. Growth Hormone Secretagogues
10. Growth Hormone Secretagogues in Clinical Practice
11. Huntington's Disease_ Third Edition
12. Living a Fully Optimized Life
13. Metabolic Syndrome_ Underlying Mechanisms and Drug Therapies
14. Peptide Protocols Volume One — William A Seeds MD
15. Peptides and Non Peptides of Oncologic and Endocrine Interest
16. Plant Bioactive Molecules
17. Super Agers An Evidence-Based Approach to Longevity — Eric Topol
18. The Carnivore Code
19. The discovery and development of liraglutide and semaglutide.partial
20. The incretin system and its role in type 2 diabetes mellitus

Continue your research

Part of our Retatrutide: Benefits & Effects guide.

• What are the potential benefits of retatrutide for patients with obesity-related conditions?
• What are the long-term health benefits of using retatrutide for weight management?
• Are there any documented benefits of retatrutide in patients with polycystic ovary syndrome?

Related topics:

• What preclinical studies have been conducted to explore the potential benefits of retatrutide?
• What Phase III clinical trials have been conducted to evaluate the efficacy of retatrutide for weight loss?
• What are the known side effects and safety concerns associated with the use of retatrutide?

📚 The 4,000+ sources behind PeptideXR →